NAFTA talks are ongoing. Email your representative and demand that they push for policies that ensure access to medicine for everyone, prioritize people and the planet over profit, and eliminate ISDS.
Call your member of Congress
Provide your zipcode and ask to be connected to your member of the House of Representatives
Tell the person who answers, or leave a message “I would like to urge my member of Congress to publicly commit to a NAFTA agreement that protects access to life-saving medicines, eliminates ISDS, and benefits working class people and the environment.”
Talk to your friends, family, doctors, and co-workers about the threat of NAFTA.
The New NAFTA: A Deal That Could Make America Sick(er)
Why Congress Should Protect Americans’ Health and Demand a Fair NAFTA
A coalition of cancer patients and others have a message for the U.S. Congress: Don’t Let NAFTA Lock In High Drug Prices
If Big Pharma corporations and the Trump administration succeed in
inserting Big Pharma’s wish list into NAFTA, we will get locked into the
bad policies that have made high U.S. medicine prices an outrage and
export these life-threatening rules to other countries.
Cancer Families joined over 100 organizations from Canada, Mexico and the United States in a January 2018 letter urging the NAFTA negotiators to ensure that any new NAFTA does not undermine access to affordable medicines. Signers included Doctors Without Borders, Oxfam, AFL-CIO, Consumers Union, Social Security Works, the American Federation of Teachers, the Alliance for Retired Americans, the NETWORK Lobby for Catholic Social Justice, People of Faith for Access to Medicines, Health Global Access Project (GAP), Public Citizen, and many more.
“Whatever other goals the Canadian, Mexican and U.S. governments have for NAFTA’s renegotiations, it is critical to do no further harm with respect to the health and access to affordable medicines of North America’s approximately 500 million people. Thus, it is vital that the NAFTA party governments reject any provisions that would expand or strengthen pharmaceutical monopolies and enforcement at the expense of access to affordable medicines.”